NBTX Overview

Company Overview: Nanobiotix is a late-stage clinical biotechnology company based in Paris, specializing in innovative therapeutic approaches, particularly in oncology and central nervous system disorders, and is listed on Euronext Paris and Nasdaq.

Voting Rights Information: As of November 30, 2025, Nanobiotix has 48,401,118 shares outstanding, with a total of 50,101,699 theoretical voting rights and 50,079,581 exercisable voting rights.

Patents and Technology: The company holds over 25 patent families related to three nanotechnology platforms aimed at improving treatment outcomes for patients.

Contact Information: For inquiries, Nanobiotix provides contact details for its communications and investor relations departments, as well as media relations contacts in France and globally.

U.S. Stock Futures: U.S. stock futures are down, with Dow futures decreasing by approximately 0.1% on Tuesday morning.

Semtech Corp Financial Results: Semtech Corp's shares fell 7.2% in pre-market trading after reporting mixed third-quarter results, with revenue of $267 million missing estimates but adjusted earnings of 48 cents per share exceeding expectations.

Other Stocks Declining: Several other stocks also experienced declines in pre-market trading, including Arcus Biosciences (-6.7%), Nanobiotix (-6.2%), and Zhihu Inc (-5.2%).

Notable Stock Movements: Advanced Micro Devices and NVIDIA saw declines of 3.8% and 4.2%, respectively, following previous gains, indicating a broader trend of falling stock prices in the tech sector.